Differential diagnosis of Alzheimer’s disease using spectrochemical analysis of blood

Paraskevaidi, Maria, Morais, Camilo L. M., Lima, Kássio M. G., Snowden, Julie S., Saxon, Jennifer A., Richardson, Anna M. T., Jones, Matthew, Mann, David M. A., Allsop, David, Martin-Hirsch, Pierre L. and Martin, Francis L

Available at http://clok.uclan.ac.uk/19897/


It is advisable to refer to the publisher’s version if you intend to cite from the work.
http://dx.doi.org/10.1073/pnas.1701517114

For more information about UCLan’s research in this area go to http://www.uclan.ac.uk/researchgroups/ and search for <name of research Group>.

For information about Research generally at UCLan please go to http://www.uclan.ac.uk/research/

All outputs in CLoK are protected by Intellectual Property Rights law, including Copyright law. Copyright, IPR and Moral Rights for the works on this site are retained by the individual authors and/or other copyright owners. Terms and conditions for use of this material are defined in the http://clok.uclan.ac.uk/policies/
Differential diagnosis of Alzheimer’s disease using spectrochemical analysis of blood

Maria Paraskevaidi1, Camilo L. M. Moraisb, Kássio M. G. Limaa, Julie S. Snowdenc,d, Jennifer A. Saxond,e, Anna M. T. Richarsonsc,d, Matthew Jonesc,d, David M. A. Manned, David Allsopo, Pierre L. Martin-Hirschf, and Francis L. Martin1,1

1School of Pharmacy and Biomedical Sciences, University of Central Lancashire, Preston PR1 2HE, United Kingdom; 2Institute of Chemistry, Biological Chemistry and Chemometrics, Federal University of Rio Grande do Norte, Natal 59072-970, Brazil; 3Cerebral Function Unit, Salford Royal Hospital, Salford M6 BHD, United Kingdom; 4Division of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Salford Royal Hospital, Salford M6 BHD, United Kingdom; 5Division of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster LA1 4YQ, United Kingdom; and 6Department of Obstetrics and Gynaecology, Lancashire Teaching Hospitals National Health Service Foundation, Preston PR2 9HT, United Kingdom

Edited by Chad A. Mirkin, Northwestern University, Evanston, IL, and approved July 31, 2017 (received for review January 27, 2017)

The progressive aging of the world’s population makes a higher prevalence of neurodegenerative diseases inevitable. The necessity for an accurate, but at the same time, inexpensive and minimally invasive, diagnostic test is urgently required, not only to confirm the presence of the disease but also to discriminate between different types of dementia to provide the appropriate management and treatment. In this study, attenuated total reflection FTIR (ATR-FTIR) spectroscopy combined with chemometric techniques were used to analyze blood plasma samples from our cohort. Blood samples are easily collected by conventional venepuncture, permitting repeated measurements from the same individuals to monitor their progression throughout the years or evaluate any tested drugs. We included 549 individuals: 347 with various neurodegenerative diseases and 202 age-matched healthy individuals. Alzheimer’s disease (AD; n = 164) was identified with 70% sensitivity and specificity, which after the incorporation of apolipoprotein E genotype (APOE ε4) information, increased to 86% when individuals carried one or two alleles of ε4, and to 72% sensitivity and 77% specificity when individuals did not carry ε4 alleles. Early AD cases (n = 14) were identified with 80% sensitivity and 74% specificity. Segregation of AD from dementia with Lewy bodies (DLB; n = 34) was achieved with 90% sensitivity and 74% specificity. Other neurodegenerative diseases, such as frontotemporal dementia (FTD; n = 30), Parkinson’s disease (PD; n = 32), and progressive supranuclear palsy (PSP; n = 31), were included in our cohort for diagnostic purposes. Our method allows for both rapid and robust diagnosis of neurodegeneration and segregation between different dementias.

Alzheimer’s disease | dementia with Lewy bodies | apolipoprotein E | differential diagnosis | spectroscopy

Neurodegenerative diseases are characterized by a common pathological mechanism of protein misfolding and aggregation and result in a progressive loss of neuronal function in the human brain/CNS and unavoidable death. Some of the common symptoms among them include problems with movement (e.g., Parkinsonism) and mental functioning (e.g., dementia). Improvements in health care and social support have resulted in many elderly sufferers of neurodegenerative disease having prolonged lives with improved quality of life. However, these diseases remain incurable, and one of the main reasons for this is likely to be that their etiology is multifactorial. It is, therefore, crucial to develop new biomarkers to better comprehend the etiology of each disease and also, for screening and diagnosis, so that appropriate clinical intervention can begin as soon as possible. Surrogate markers of disease progression will also facilitate the development of new treatments, and this has led to an increased interest over recent years in the discovery of biomarkers for diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), dementia with Lewy bodies (DLB), vascular dementia, and frontotemporal dementia (FTD). AD accounts for 60–70% of all types of dementia, with symptoms of memory loss; language problems; disorientation in identity, time, and place; cognitive decline; and eventually, death. Various pathological mechanisms contribute to brain damage, including amyloid deposition (1), neurofibrillary tangle formation (2), oxidative stress (3), inflammation (4, 5), and lipid dysregulation (6). A major genetic risk factor for AD is the ε4 allele of apolipoprotein E (APOE). APOE protein is involved in cholesterol distribution throughout the body, including brain, and exists in three different isoforms (E2, E3, E4) (7). Possession of one or more APOE ε4 alleles increases the risk of developing late-onset AD, reduces age of onset, and is associated with a higher cerebral amyloid plaque load and promotion of neurofibrillary tangle formation (8, 9).

Current approaches for diagnosing AD include measurement of amyloid-β (Aβ; specifically Aβ42) and total tau (T-tau) or phosphorylated tau (P-tau) levels in cerebrospinal fluid (CSF), structural neuroimaging techniques (MRI or computerized tomography), PET imaging of brain amyloid, or inflammation and batteries of neuropsychological tests (10). Usually, a combination of more than one test is necessary to provide a working diagnosis,

Significance

Vibrational spectroscopy is an ideal technique for analysis of biofluids, as it provides a “spectral fingerprint” of all of the molecules present within a biological sample, thus generating a holistic picture of the sample’s status. Neurodegenerative diseases lack early and accurate diagnosis, and tests currently used for their detection are either invasive or expensive and time-consuming. This study used blood plasma to diagnose and differentiate various neurodegenerative diseases; the achieved sensitivities and specificities are equal to, or even higher than, the ones obtained by clinical/molecular methods. Herein, we show that spectroscopy could provide a simple and robust diagnostic test. Additional work should include asymptomatic individuals for an early screening test and exploration of neurodegenerative diseases at all stages of severity.


The authors declare no conflict of interest.

This article is a PNAS Direct Submission.

Freely available online through the PNAS open access option.

Data deposition: The data (raw spectra and preprocessed spectra) reported in this paper are available at the publicly accessible data repository Figshare (doi: 10.6084/m9.figshare.5309797).

1To whom correspondence may be addressed. Email: MParaskevaidi@uclan.ac.uk or flmartin@uclan.ac.uk.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1701517114/-/DCSupplemental.
while a definitive diagnosis can still only be given postmortem with histopathological examination (11). Brain scans present disadvantages, as they are expensive and time-consuming. CSF would be an optimal source for AD biomarkers, as it is in contact with the brain, allowing biochemical changes in the brain to be directly monitored. However, CSF collection is not universally obtainable, as it is invasive (lumbar puncture) and can be unpleasant for patients; therefore, not all clinicians are willing to take such samples routinely. Five hundred milliliters of CSF is discharged into the bloodstream every day, and therefore, alterations in CSF content can also facilitate discovery of blood-borne biomarkers of neurodegenerative disease (12).

Research has, therefore, focused on blood-based methods for diagnosis of neurodegenerative diseases. A major goal is the detection of AD at a very early stage, even before the patient becomes symptomatic (10, 13). Early diagnosis is crucial, as once the patient appears with clinical symptoms, the damage that has occurred in the brain may already be irreversible. However, if at-risk individuals are identified early, it may be possible to delay or even prevent additional progression of the disease by administration of drugs that decrease Aβ production or aggregation (preventing plaque formation) or tau protein aggregation (preventing tangle formation) (14). The diagnostic accuracy of existing biomarkers has been previously reported to vary from ~70 to ~95% (10, 13, 15, 16); however, most of these cannot be used routinely because of their high cost and laborious sample processing.

Vibrational spectroscopy, including FTIR and Raman spectroscopy, has been widely used to discriminate and classify normal and pathological populations using cells, tissues, or biofluids (17–19). Readily accessible biofluids, such as blood plasma/serum, saliva, or urine, are considered ideal for clinical implementation because of routine methods of collection as well as their minimal sample preparation. Interrogation of these samples with spectroscopic techniques allows for the generation of a “spectral fingerprint,” which subsequently facilitates the discrimination of the different populations and identification of potential biomarkers. In the past few years, blood-based FTIR and Raman spectroscopy have been used for diagnosing, screening, or monitoring the progression/regression in a variety of diseases (20, 21). Spectroscopic techniques have many advantages over conventional molecular tests (e.g., ELISA), as they allow the investigation of a range of different molecules simultaneously instead of studying isolated molecules; thus, they are ideal for complicated, multifactorial diseases. They are also rapid, cost-effective, and nondestructive, which renders them a perfect candidate for translation to clinical.

In this study, attenuated total reflection FTIR (ATR-FTIR) spectroscopy was used to interrogate blood plasma samples from individuals with various neurodegenerative diseases. One of our goals was to differentiate AD as well as early AD patients from healthy control (HC) individuals and provide meaningful biomarkers that would assist in a more conclusive clinical diagnosis. We also took into consideration the APOE genotype and age of our participants as confounding factors. The second major objective of this study was to determine the spectral wavenumbers that allow segregation of AD from other dementias, such as DLB and FTD, where differential diagnosis—especially in early stages—can be challenging. The segregation of AD from DLB is of particular clinical importance, since accurate diagnosis is necessary for suitable medication. DLB is the second most common form of dementia (10–15% of all dementias) and shares characteristics with AD, leading to frequent misdiagnosis (22). Although AD remains the most common neurodegenerative disorder, other less common diseases, such as progressive supranuclear palsy (PSP) and PD, were also included for diagnostic purposes.

**Results**

**AD Vs. HC.** We primarily focused on the discrimination of AD patients from HCs; Fig. 1A and B shows the preprocessed spectra (cut, rubber band baseline corrected, vector normalized) at the fingerprint region (1,800–900 cm⁻¹) and high region (3,700–2,800 cm⁻¹), respectively. At the fingerprint region (Fig. 1A and Fig. SI4), the AD group showed slightly higher peaks at 1,650–1,650 cm⁻¹ [P < 0.005, 95% confidence interval (95% CI) = −0.005, 0.0004, stretching vibration (νs) of (C = O), Amide I, proteins] and 1,540–1,530 cm⁻¹ [P = 0.003, 95% CI = −0.0031, −0.0007, bending vibration (νb) of (N-H), Amide II, proteins] as well as lower peaks at 1,750–1,735 cm⁻¹ [P = 0.006, 95% CI = 0.0006, 0.0035, ν(C = O) of lipids], 1,590–1,580 cm⁻¹ [P = 0.254, 95% CI = −0.0008, 0.0003, δ(N-H) of Amide II, proteins], 1,470–1,430 cm⁻¹ [P = 0.0002, 95% CI = 0.002, 0.006, δ(CH2) of lipids and proteins], 1,220–1,160 cm⁻¹ [P = 0.0035, 95% CI = 0.0016, 0.0084, carbohydrates, asymmetric stretching (νas) of PO₃⁻ of DNA/RNA], and 1,150–1,040 cm⁻¹ [P = 0.0002, 95% CI = 0.0057, 0.0185, carbohydrates and symmetric stretching (νs) of PO₃⁻ of DNA/RNA]. At the higher region (Fig. 1B and Fig. SI5), the AD group showed lower peaks at 2,950–2,850 cm⁻¹ [P < 0.0004, 95% CI = 0.021, 0.017, ν(CH3) of lipids] and slightly higher peaks at 3,550–
Classification of AD and HC Before the Incorporation of APOE e4 Genotype and Age Information. Classification of AD and HC was performed in both IR spectral regions of interest using PCA-LDA, principal component analysis followed by quadratic discriminant analysis (PCA-QDA) (Figs. S2 and S3), successive projection algorithm followed by linear discriminant analysis (SPA-LDA), successive projection algorithm followed by quadratic discriminant analysis (SPA-QDA) (Figs. S4 and S5), genetic algorithm followed by discriminant analysis (GA-LDA), and genetic algorithm followed by quadratic discriminant analysis (GA-QDA) (Figs. S6 and S7). The best classification ratios were obtained after GA-LDA for the fingerprint region (Fig. 2A and C) and PCA-QDA for the high region (Fig. 2B and D). GA-LDA used 23 wavenumbers (Fig. 2A) determined from the minimum cost function G (Fig. S6C), which identifies the optimal number of wavenumbers to be used. Fig. 2C is the scores plot illustrating classification by GA-LDA. Sensitivity and specificity achieved by GA-LDA, providing 80% sensitivity and 74% specificity. The selected wavenumbers for GA-LDA classification were 964, 1,014, 1,072, 1,122, 1,234, 1,296, 1,308, 1,312, 1,342, 1,369, 1,396, 1,420, 1,508, 1,531, 1,535, 1,601, 1,651, 1,690, 1,705, 1,763, and 1,786 cm$^{-1}$ (Fig. 2A).

Classification of AD and HC After the Incorporation of APOE e4 Genotype and Age Information. Similar to before, all of the available chemometric techniques were applied after incorporation of APOE e4 and age information. GA-LDA provided higher accuracy than before, achieving sensitivity of 72% and specificity of 77% in individuals with no APOE e4 alleles (Fig. 3 A and B and Fig. S8 A, C, and E). From the comparison of AD patients and controls with only two APOE e4 alleles, the best sensitivity and specificity were achieved by GA-QDA—each equal to 86% (Fig. 3 C and D and Fig. S8 B, D, and F).

The same algorithms were applied to further investigate the effect of age on classification; GA-LDA provided the highest sensitivity and specificity for both comparison groups: AD vs. HC (<65 y old) and AD vs. HC (≥65 y old), respectively. In the comparison of the two classes of <65 y of age, sensitivity was 68%, and specificity was 65% (Fig. 3 E and F). In the ≥65-y-old age group comparison, sensitivity and specificity were equal to 66 and 67%, respectively (Fig. 3 G and H).

Classification of Early AD and HC. Our dataset included 14 cases of early AD; as previously shown, all of the classification algorithms were applied to compare early AD with HC (Fig. 4C). The chemometric technique that achieved the highest accuracy was GA-LDA, providing 80% sensitivity and 74% specificity. The selected wavenumbers for GA-LDA classification were 964, 1,018, 1,122, 1,126, 1,138, 1,192, 1,277, 1,342, 1,358, 1,393, 1,396, 1,612, 1,636, and 1,678 cm$^{-1}$ (Fig. 4B).

Duration of AD. Patients were further classified and investigated according to disease duration to gain information on AD progression. Three different groups were examined based on duration: the first group (0.5–1 y) has 32 AD patients, the second group (1.5–5 y) has 111 patients, and the third group (6–18 y) has 17 patients. Relevant information was not available for four AD patients. Six spectral wavenumbers, corresponding to important biomolecules, showed substantial differences between the groups.
Lipid-to-Protein, Phosphate-to-Carbohydrate, and RNA-to-DNA Ratios Related to Age. All individuals within the AD group were compared according to their age; patients were grouped into <65- and ≥65-y-old groups (Fig. 6d); people ≥65 y old and older are at higher risk of developing AD, and therefore, this age was used as a threshold value. Fig. 6d represents a 1D scores plot and was generated after cross-validated PCA-LDA (P = 0.6440, 95% CI = −0.0039, 0.0070).

To further establish potential biomarkers and account for alterations between the different age groups of AD patients and HCs, we calculated the intensity ratio of six important spectral regions. Fig. B–D represents the lipido-protein ratio (1,450/1,539 cm\(^{-1}\)), phosphate-to-carbohydrate ratio (1,045/1,545 cm\(^{-1}\)), and RNA-to-DNA ratio (1,060/1,230 cm\(^{-1}\)), respectively. The two extra tables shown in Fig. 6 display the different subgroups for each class as well as their mean age (±SD). Subgroup A represents individuals of <65 y of age, and subgroup B represents individuals of ≥65 y of age.

No statistically significant differences were seen for the ratios within the HC or within AD groups. All of the different ratios, lipid-to-protein, phosphate-to-carbohydrate, and RNA-to-DNA, showed a decreasing trend for AD patients compared with HC. More specifically, in the lipid-to-protein ratio, statistically significant differences were seen after the comparison of HC (≥65 y old) vs. AD (<65 y old; P = 0.002, mean rank difference: 60.23) and HC (≥65 y old) vs. AD (≥65 y old; P = 0.014, mean rank difference: 39.82). Lastly, the RNA-to-DNA ratio showed statistically significant differences for HC (<65 y old) vs. AD (≥65 y old; P = 0.037, mean rank difference: 49.89) and HC (≥65 y old) vs. AD (<65 y old; P = 0.02, mean rank difference: 49.69).

Other Types of Neurodegenerative Diseases. Another objective of this study was the identification of biomarkers that could be used for the diagnosis of less common neurodegenerative diseases (i.e., DLB, PD, FTD, and PSP); FTD and PSP patients were specifically selected for additional investigation, as the high...
number of subjects (>30) allowed for more robust conclusions. We also attempted to differentiate AD patients from patients with other types of dementia, such as DLB and FTDP.

Initially, all of the different neurodegenerative pathologies were compared; the “other” group, containing less common neurodegenerative diseases, was also included to further validate our results and represent a pragmatic cohort. To visually account for similarities and differences between the various classes, we first generated the scores plots after cross-validated PCA-LDA (Fig. 7). With the use of linear discriminant 1 (LD1), the differentiation between the AD and HC was more prominent (Fig. 7A), while linear discriminant 2 (LD2) segregated better DLB and PD from HC (Fig. 7B). The other group was better separated from the HC when LD1 was used (Fig. 7A). LD1 was also responsible for the better segregation of FTD and PSP patients from HC (Fig. 7C). DLB and PD were not statistically different from HC when using LD1 (for the comparison between DLB and HC, \( P = 0.0521 \), 95% CI = 0.0000; 0.0033; for the comparison between PD and HC, \( P = 0.3315 \), 95% CI = 0.0282, 0.0089) (Fig. S9 A and B), whereas FTD and PSP were both statistically different from HC, with \( P = 0.0041 \), 95% CI = 0.0264, 0.0049 and \( P < 0.0001 \), 95% CI = 0.0439, 0.0021, respectively (Fig. S9 C and D).

Of particular focus was the differentiation of AD and DLB. Chemometric techniques (PCA-LDA/PCA-QDA, SPA-LDA/SPA-QDA, and GA-LDA/GA-QDA) were applied, as previously, toward classification of AD vs. DLB (Fig. 8). The best classification ratios were achieved after PCA-QDA, giving sensitivity and specificity of 90%. Statistical analysis was also conducted after cross-validated PCA-LDA, and significant differences were found between the two groups (\( P = 0.178 \), 95% CI = 0.0012, 0.0157) (Fig. S10A). Finally, for the comparison of AD vs. FTD patients, significant differentiation was achieved after cross-validated PCA-LDA (\( P = 0.0040 \), 95% CI = 0.0041, 0.0216) (Fig. S10B).

**Discussion**

Using blood-based vibrational spectroscopy, we achieved results with significant clinical relevance at multiple levels. ATR-FTIR spectroscopy has been proven to be capable of detecting differences not only between patient and healthy groups but also, between various neurodegenerative dementias.

Overall, our results are in line with findings of previous studies, and most of the biomolecules that we identified, as contributors to the discrimination between AD and HC, have been previously described as potential biomarkers (10, 16, 23, 24). Generally, the IR region of 1,700–1,600 cm\(^{-1}\) is indicative of the protein secondary structure and could reflect protein conformational changes. A slight increase of the intensity at the Amide I region (1,650–1,630 cm\(^{-1}\); \( P = 0.1069 \), 95% CI = 0.0008, 0.0008), observed in our AD patients, could be due to increased levels of \( \beta \)-plaques. In a recent study, using a more complex setting with a specialized, immuno-IR sensor, it was shown that the structural changes of \( \beta \)-peptide from \( \alpha \)-helix to \( \beta \)-sheet, seen in AD, can be detected by a significant downshift of the Amide I region (1,643 cm\(^{-1}\)), and this further proves the importance of this region (13). Similar results were seen in another study, which analyzed protein solutions containing soluble and aggregated forms of tau protein (random coil and \( \beta \)-sheet, respectively); in this case, a transition from a maximum peak at 1,650 cm\(^{-1}\) to a peak at 1,630 cm\(^{-1}\) was evident (25). However, in our study, statistically significant differences were not observed at this specific region. The increase at the Amide II region (1,540–1,530 cm\(^{-1}\); \( P = 0.0096 \), 0.0096) could potentially be attributed to the overall accumulation of the above-mentioned proteins. The decrease in lipids (1,750–1,735 to 1,470–1,430 cm\(^{-1}\)) and free radicals caused by the loss of phosphoric acid and strand breaks also caused by hydroxyl radicals (27). The differences seen at the higher region could also occur because of disruption of phospholipid cell membranes (lower intensity at 2,950–2,850 cm\(^{-1}\)) and free radicals (higher intensity at 3,550–3,450 cm\(^{-1}\)). Multivariate approaches were further used to account for more detailed differences between the classes.

All of the six chemometric techniques used for classification between AD and HC identified differences that led to classification. The algorithms that achieved best classification were GA-LDA at the fingerprint region and PCA-QDA at the higher region. The sensitivity and specificity values found after the GA-LDA model at the fingerprint region (70%) were remarkable, considering that the spectral differences seen between AD and HC were very subtle. However, sensitivity and specificity at the higher region were slightly lower (68%), indicating the necessity of using the lower biofingerprint region toward the classification of AD samples rather than the higher region.

In a recent, large-scale study, which gathered information on 919 patients who had died and been autopsied, clinical diagnostic methods provided sensitivity ranging from 70.9 to 87.3% and specificity ranging from 44.3 to 70.8% (28). Having said that, an earlier study using 228 postmortem samples from the Manchester brain bank showed an overall agreement of 97% between clinical and pathological diagnoses of various neurodegenerative diseases (29). Clinical diagnosis of AD, specifically, was made with 97% sensitivity (four patients with pathologically confirmed AD had a different clinical diagnosis) and 100% specificity (a clinical diagnosis of AD was never wrong) (29). With regards to the subjects that we used for the specific study, it should be noted that, of the...
2,450 samples so far accrued, 60 brains have been recovered; 14 thereof had a clinical diagnosis of AD, which was confirmed by pathological findings in 13 of them, whereas the other patient actually had corticobasal degeneration (CBD). Incidentally, there were four patients who had a clinical diagnosis of frontotemporal lobar degeneration—three with semantic dementia, one with FTD—and were identified as AD based on histopathology. However, none of these patient samples were available for a subgroup analysis in our spectroscopic study.

The performance of our chemometric analyses showed excellent agreement with these previous results. Although all patients with AD fulfilled relevant diagnostic criteria, it is well-known that there is clinical heterogeneity, with some patients showing disproportionate impairment of language, memory, frontal behavioral changes or orientation, and praxis. These may reflect topographic changes in the distribution of brain pathology in the early stages of the disease, partially in line with APOE genotype (30), and might influence the outcomes of the spectral analysis. Having said that, even if AD patients did show clinical uniformity overall, they could still have different phenotypes because of epigenetic alterations and/or environmental exposure that could influence the result (28, 31). Therefore, a clinical diagnosis would never reach 100% accuracy but rather, ~80–90%. At the same time, some of the HC participants will inevitably have preclinical AD, since they are more or less age-matched to this group, also leading to rates lower than 100%. Unfortunately, preclinical diagnosis of these diseases is problematic, because there is, as yet, no really robust system to test for “prodromal” disease cases. Another

Fig. 6. Lipid-to-protein, phosphate-to-carbohydrate, and RNA-to-DNA ratios related to age. (A) Scores plot after cross-validated PCA-LDA showing differences and similarities of AD patients before and after the age of 65 y old; no significant differences were found after statistical analysis ($P = 0.6440, 95\% CI = -0.00391, 0.0070$). (B–D) Intensity ratios of important spectral regions: lipid-to-protein (1,450/1,539 cm$^{-1}$), phosphate-to-carbohydrate (1,045/1,545 cm$^{-1}$), and RNA-to-DNA (1,060/1,230 cm$^{-1}$), respectively. Data are expressed as mean ($\pm$SD). The two tables shown next to these graphs show the different subgroups and their mean age ($\pm$SD). *$P < 0.05$; **$P < 0.005$. 

<table>
<thead>
<tr>
<th>AD</th>
<th>Age group (years)</th>
<th>Mean age ($\pm$ SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total (n=164)</td>
<td>50-88</td>
</tr>
<tr>
<td></td>
<td>Subgroup A (n=54)</td>
<td>&lt;65</td>
</tr>
<tr>
<td></td>
<td>Subgroup B (n=106)</td>
<td>$\geq$ 65</td>
</tr>
<tr>
<td></td>
<td>Unknown (n=4)</td>
<td>-</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>HC</th>
<th>Age group (years)</th>
<th>Mean age ($\pm$ SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total (n=202)</td>
<td>23-90</td>
</tr>
<tr>
<td></td>
<td>Subgroup A (n=78)</td>
<td>&lt;65</td>
</tr>
<tr>
<td></td>
<td>Subgroup B (n=118)</td>
<td>$\geq$ 65</td>
</tr>
<tr>
<td></td>
<td>Unknown (n=6)</td>
<td>-</td>
</tr>
</tbody>
</table>
possible explanation for the obtained classification values in this study could be the inclusion of all AD patients in one group without additional classification to different stages (mild, moderate, severe), as these were not fully recorded; this was also shown to adversely affect the results in a recent study, when AD patients of all stages were included in the same group (32). Nevertheless, in our AD dataset, we had 14 cases of early AD, and thus, we were able to conduct a subgroup analysis comparing them with the healthy subjects. The achieved sensitivity and specificity were 80 and 74%, respectively, implying that this spectroscopic technique may serve as a diagnostic tool for early AD as well; however, results should be interpreted with some caution because of the small number of early AD cases. In general, very high sensitivities/specificities should not be expected anyway, as the changes in the biochemical composition of blood plasma are relatively minor, compared with changes in CSF, for example, and do not necessarily reflect all possible alterations happening in the brain during AD progression (24).

*APOE* was also investigated, as it is a major risk factor for AD; homozygous e4 individuals develop the disease 10–20 y earlier than the others (33), while *APOE* e3 is considered “neutral,” and *APOE* e2 is believed to serve a protective role (34). Furthermore, one e4 allele increases the risk threefold, while two e4 alleles increase the risk eightfold compared with the situation with no e4 alleles. Different *APOE* genotypes would also cause differences in lipid composition and by extension, spectral information, and they could potentially “cloud” the issue when looking for a diagnostic. Therefore, after the incorporation of *APOE* e4 information, the achieved classification results were noticeably higher, with sensitivity and specificity reaching 72 and 77% when the subjects had no *APOE* e4 alleles as well as 86 and 86% when the subjects had one or two *APOE* e4 alleles. After classifying AD and HC by age, lower values were achieved, suggesting that integration of *APOE* genotype is more important toward AD diagnosis. This could further support our aforementioned hypothesis, according to which differences in lipid deposition, caused by the presence of different *APOE* genotypes, could hide important spectral information; this would justify the higher classification values after classifying by genotype but not by age. In conclusion, these values for sensitivity/specificity, after consideration of *APOE* genotype information and along with the ease of sample collection and preparation, should ultimately allow the implementation of this test into a clinical setting.

From our analysis on AD duration, we found evidence of alterations being detectable, which correlate with duration. The increasing trend seen at 1,547 cm⁻¹ is indicative of proteins predominantly in β-sheet conformation [Amide II, N-H bending, and C-N stretching (17)] and could potentially be attributed to an increased level of Aβ or more probably, tau proteins. One might presume that, by the time of clinical diagnosis, Aβ levels may well have peaked according to the amyloid cascade hypothesis, whereas tau pathology should still increase, spreading from temporal lobes into other neocortical regions. However, a decreasing trend is seen at 1,504 cm⁻¹, which is again indicative of Amide II (proteins), but this time coming mainly from C-H bending vibrations of the proteins’ phenyl rings (17); this may be because of damage caused by reactive oxygen species (ROS) during oxidative stress (26), as phenyl rings are readily damaged by ROS. These peaks could provide information on progression and pathophysiology of AD, and a combined ratio with other important wavenumbers may serve as a potential biomarker. A decreasing trend is also seen at 1,369, 1,219, and 1,080 cm⁻¹, which are assigned to cytosine/guanine and asymmetric and symmetric vibrations of phosphate of nucleic acids, respectively (17). We speculate that this general decrease in nucleic acids is caused by the increased levels of ROS that could lead to strand breaks and loss of phosphoric acid (27).

In a relatively recent study, an elevated level of a specific type of collagen in the brain (collagen VI) was suggested to protect individuals against AD (35). The same study also pointed out that neurons of the brain were the source of this collagen VI. Therefore, this made us hypothesize that the progressive degradation of nerve cells coming with disease duration could potentially undermine their ability to produce collagen and that may explain the statistically significant decrease that we observe in individuals after 1 y of AD (i.e., peak at 1,034 cm⁻¹).

After classification of the AD group into different age groups, the differences were not significant, suggesting that age difference alone is inadequate for discrimination when an individual has already developed the disease. Moreover, after calculation of different ratios of important spectral bands, potential biomarkers
were established, and a classification process was facilitated by
the generation of distinct patterns. Significant differences were
seen after comparison of different age groups of HC and AD,
and a combined ratio may serve as a more reliable biomarker.

In this study, we also incorporated a range of different neu-
rodegenerative diseases, apart from AD, and achieved satisfac-
tory segregation and classification results. The distinctive patterns
seen between AD, DLB, and FTD may represent different
pathological changes (36) and were mostly attributed to proteins
and lipids. Accurate separation of DLB from AD is of high im-
portance, as it would allow for appropriate medication/manage-
ment and therefore, impact on outcomes; for instance, it is
established that cholinesterase inhibitor treatment is more effective
in DLB than AD patients (37). The high sensitivity and
specificity (90%) achieved for distinguishing AD from DLB are
outstanding and would provide an excellent diagnostic test toward
clinical implementation. By reduction of misdiagnosed DLB cases
and administration of appropriate drugs, many individuals would
benefit by getting the appropriate clinical management. Potential
biomarkers have also been suggested toward the diagnoses of
DLB, PD, FTD, and PSP. It should be noted that PD and DLB
did not show significant segregation from each other, which sug-
gests common characteristics; the presence of Lewy bodies (i.e.,
α-synuclein), which is a hallmark of both diseases, is the main cul-
prit for this similarity (38, 39).

A strength of this study is the large patient cohort, especially in
the AD and HC groups, which to our knowledge, has not been
previously repeated with similar techniques. However, some of the
other diseases [motor neuron disease (MND), vascular dementia,
etc.] are less common than AD; thus, the number of patients was
limited. Additional exploration of these diseases using larger co-
horts is required. Also, for prospective recruitment, patient char-
acteristics should be recorded in more detail along with the stage
of severity—mild (early stage), moderate (middle stage), and se-
vere (late stage)—whenever possible.

Currently, there is no single definitive medical test for di-
agnosing AD. In terms of biological markers, the most widely
studied molecules are undoubtedly Aβ and P-tau or T-tau. How-
ever, numerous studies attempting to diagnose AD using blood
have shown controversial results (40). Specifically, plasma Aβ-
42 and Aβ-40 levels have been seen to increase or decrease in AD
patients compared with controls. Plasma total Aβ and Aβ-42 levels
have shown inconsistent changes depending on whether an indi-
vidual presented with familial or sporadic AD. Increase of Aβ-
42 has been reported in women with AD (41) and women with
mild cognitive impairment (MCI) but not men. Other studies in plasma have found no
differences at all between AD and controls; ratios of Aβ-42/
Aβ-40 have also been conflicting, as some found that an elevated ratio
predicts AD, while others found the opposite or no difference at all
(41, 42). Several reasons have been implicated for these findings,
such as the shift of Aβ levels over time and among individuals or
the different stages of AD (42); this could potentially justify the
nonsignificant increase (P = 0.1069, 95% CI = −0.005, 0.0005) that
we observed at the Amide I region (1,650–1,630 cm−1) comparing
AD patients with HCs. A recent metaanalysis of 231 studies con-
cluded that plasma Aβ-42 and Aβ-40 were not strongly associated
with AD and thus, should not be used in clinical practice (43).

Levels of tau protein in blood have also been investigated with
the hope of diagnosing AD. A recent study reported elevated
T-tau levels in AD patients compared with MCI and controls but
found significant overlap between MCI and AD as well as no
correlation between tau levels in CSF and plasma (44). Another
study reported increased level of T-tau protein in AD, which
when combined with the levels of Aβ-42, achieved improved
sensitivities and specificities (80 and 82%, respectively) in dif-
ferentiation of AD from MCI (45). The above-mentioned meta-
analysis (43) also concluded that increased plasma level of
T-tau was the only blood biomarker that discriminated AD
from controls; however, it was pointed out that this finding would
need additional verification in larger cohorts. Overall, there is
still lack of optimal and reliable blood-based biomarkers that
would allow screening of preclinical AD in a clinical setting (46).

Most of the developed tests are for research use only, and this
emphasizes the need to move on to new analytical approaches.

The available drugs for AD can only temporarily alleviate symptoms and do not treat the disease. The National Institute on
Neurological Disorders and Stroke and the Alzheimer’s Association have recommended clinical trials, focusing on the reduction of Aβ and tau levels, that suggest that there are more contributing factors/biomolecules to
be explored. Biospectroscopy investigates a range of different
biomolecules simultaneously, which could be advantageous in
multifactorial diseases, like AD. In this study, we have achieved
diagnosis of AD with an accuracy of ~70–85% as well as
differential diagnosis of AD and DLB with 90% sensitivity and
specificity, which are outstanding considering the several
overlapping features.

At the same time, biospectroscopy is rapid, cost-effective, and
less laborious than other blood tests that require expensive anti-
body assays. For instance, a typical ELISA (96-well plate) has been
calculated to cost approximately $1,000, with three kits
needed to quantify three core biomarkers of AD disease: Aβ,
T-tau, and P-tau (42, 43). Finally, this spectroscopic method could be used
to further investigate individuals in combination with other clini-
cally used neuropsychological tests and thus, help the clinician to
decide whether to proceed to more specialized and expensive tests.

In summary, we have shown excellent diagnostic performance of
our method for AD—especially after the APOE ε4 in-
formation—as well as for other neurodegenerative diseases. Our
data suggest specific “fingerprint” regions capable of discrimi-
nating between pathological and healthy individuals as well as
differentiating among the different types of dementia. Early AD
cases were also segregated from HC with a high degree of sen-
sitivity and specificity. Here, we would like to emphasize that,
although we acknowledge the importance of diagnosing AD at
an early stage, we also believe that there are some hurdles to
overcome in diagnosing AD at any stage. Blood spectroscopy, as
described in this study, would provide an alternative to current
tests, such as CSF or MRI tests. A prospective study, recruiting a larger
number of individuals in healthy or predementia (MCI) state,
would be required to confirm spectroscopy’s ability to perform as
a screening test. By monitoring the latter individuals’ progression
throughout the years, it would be possible to detect preclinical
AD and establish early biomarkers implying the appearance of
the disease. The ultimate aim would be to identify individuals
destined to develop AD long before the symptoms occur and
cease—or at least slow down—brain damage before it is too late.

Materials and Methods

Patients and Ethics. Blood samples were collected at Salford Royal Hospital,
with informed consent obtained before enrolment in accordance with Local
Ethical Approval (05/Q1405/24) conferred by North West 10 Research Ethics
Committee Greater Manchester North). This study included 549 individuals with
various neurodegenerative diseases as well as age-matched healthy
individuals, usually spouse controls. Patients with dementia were diagnosed
according to a battery of psychological testing (Manchester Neuropsychology
Inventory) performed at a specialist referral center (Cerebral Function Unit at
the Greater Manchester Neurosciences Centre, Salford Royal Hospital). Pa-
tients with movement disorder but without apparent cognitive impairment
were assessed in a specialist movement disorder clinic at Salford Royal
Hospital, and diagnosis of PD, PSP, multiple system atrophy (MSA), or CBD was
ascribed by consultant neuropsychologists with expertise in this area. Also, patients
with MND were assessed and diagnosed in Manchester MND Care Centre at
Salford Royal Hospital. At time of diagnosis, patients were not receiving any
medications, such as anticholinesterase treatments, which might affect the
outcomes. Most patients receive MRI scans, but these were used only to
support the neuropsychological outcomes.

The patient cohort was subgrouped in different classes depending on the type
of neurodegenerative pathology: 164 patients with AD, 34 patients with DLB,
32 patients with PD, and a separate group named other containing 117 other
less common neurodegenerative diagnoses. The other group consisted of 10 patients
with CBD, 30 with FTD, 4 with MND, 5 with MSA, 20 with progressive nonfluent
aphasia (PNFA), 31 with PSP, 14 with semantic dementia, and 3 patients with
vascular dementia. The HC group was composed of 202 individuals who were
recruited with informed consent as above. The information on clinical and
demographic data is summarized in Table 1. A power test, using power of 80% (r test, confidence level of 95%) based on the training spectra set, indicated a number of 368 samples to be used for the comparison of AD with DLB. However, we have used 366 samples for AD vs. HC (power = 86%) and 198 samples for AD vs. DLB (power = 92%), covering larger data variability.

Sample Collection and Preparation. Whole-blood samples were collected into EDTA tubes and centrifuged at 1,130 × g at 4 °C for 10 min to separate erythrocytes from plasma. Plasma was collected in 0.5-ML clean plastic tubes, stored at −80 °C, and thawed at room temperature when necessary for experiments. After frozen samples were thawed, 50 μL from each were deposited on IR-reflective glass slides (MirriR Low-E slides; Kevel Technolo-
gies) and left to air dry for ≈30 min before spectroscopic interrogation.

APOE Genotyping. DNA was extracted by routine methods from blood samples of patients and control subjects. APOE alleles were determined with PCR (47). AD patients and HC individuals were classified for comparison into different categories depending on their APOE genotype (Table S1). Because of the established importance of APOE ε4 alleles in AD, we categorized our cohort into different groups to establish whether better classification is achieved. Both AD and HC individuals were categorized into two groups: one with no APOE ε4 alleles and another with one or two APOE ε4 alleles. AD patients with one or two APOE ε4 alleles (n = 142), and similarly, patients with one or two APOE ε4 alleles (n = 88) were compared with HCs with no APOE ε4 alleles (n = 49).

ATR-FTIR Spectroscopy. Spectra were obtained using a Tensor 27 FTIR spectrometer with Helios ATR attachment (Bruker Optics Ltd) operated by OPUS 5.5 software. The sampling area, defined by the internal reflection element, which was a di-
amon crystal, was 250 × 250 μm. Spectral resolution was 8 cm−1 with two times zero-filling, giving a data spacing of 4 cm−1 over the range 4,000-400 cm−1. Spectra were acquired from 10 different locations of each sample to minimize bias. The diamond crystal was cleaned with distilled water and dried every time before moving to the next sample; a background spectrum was also taken after the analysis of each sample to account for changes in ambient conditions.

Preprocessing of Spectra. A in-house-developed IRootLab toolbox (trevisian, 
github.io/irootlab) was implemented within MATLAB R2012b software (Math-
Works) for both preprocessing and computational analysis of the data. Pre-
processing corrects problems associated with spectral data acquisition and increases the robustness of subsequent multivariate analyses. Spectra were preprocessed by two different methods and at two different regions of the mid-
IR spectrum; the first region examined was the biochemical “fingerprint region” at 1,800–900 cm−1, and the second was a higher region at 3,700–2,800 cm−1, which is representative of –OH levels and lipid concentration. The first pre-
processing method used rubber-band baseline correction followed by vector normalization and was included for better visualization. However, the second method, using Savitzky–Golay second-order differentiation (second-order poly-
nomial and nine filter coefficients) and vector normalization, was the main approach used before additional multivariate analysis and classification. The second derivative was preferable as a preprocessing step, as it allows over-
lapping peaks to be resolved and accounts for differences in more detail (48).

The unsophisticated approach of DBM spectra was initially implemented to subtract the mean spectra of two different classes and account for dif-
f erences; a peak-detecting algorithm was used to identify the most prom-
inent peaks responsible for the segregation (49).

Computational Analysis and Classification. Computational analysis of all spectra was performed using MATLAB with IRootLab and PLS Toolbox 7.9.3 (Eigenvector Research, Inc.). The multivariate analysis techniques used in this study were composed of PCA-LDA/PCA-QDA, SPA-LDA/SPA-QDA, and GA-LDA/GA-QDA. PCA is an unsupervised technique that reduces the spectral data space to principal components (PCs) responsible for the majority of variance in the original dataset. This technique looks for inherent similarities/differences and provides a scores matrix representing the overall “identity” of each sample, a loadings matrix representing the spectral profile in each PC, and a residual matrix containing the unexplained data. The scores information can be used for exploratory analysis, providing possible classification between data classes. However, sometimes, PCA alone may not be enough, as it cannot distinguish whether the differences come from “within-class” or “between-
class” variability (48, 50). For this reason, LDA, which is a supervised tech-
nique, is often applied after PCA to maximize the distance between the classes and minimize the distance within a class; consequently, PCA-LDA allows for better segregation.

For this study, the –230 variables (after the preprocessing) were reduced into 10 PCs that represented >95% of the variance. After mean-centering of the data, cross-validated PCA-LDA was performed to prevent overfitting of the data [with k-fold (k = 10) and leave-one-out validation]. After cross-
validated PCA-LDA, information was visualized from 1D scores plots (using LD1 or LD2), while identification of specific wavenumbers accounting for separation was achieved from loading plots.

QDA is another supervised technique of discriminant analysis based, just like LDA, on the Mahalanobis distance between objects of classes. The main differences between the LDA and QDA are in the calculation of the classi-
fication score, in which QDA presents a more sophisticated approach ac-
counting for different variance structures in the classes being analyzed. The LDA technique assumes that the classes have similar variance matrices, whereas QDA forms a separated variance model for each class (51). LDA and QDA classification scores are calculated as follows:

$$LDA: \quad L_k = (x_i - \mu_k)^T \Sigma^{-1}_{k} (x_i - \mu_k) - 2 \log \frac{\lambda_k}{\pi}$$

$$QDA: \quad Q_k = (x_i - \mu_k)^T \Sigma^{-1}_{k} (x_i - \mu_k) + \log \left( \frac{\lambda_k}{\pi} \right) - 2 \log \frac{\lambda_k}{\pi}$$

where $x_i$ is a measurement vector for sample i, $\mu_k$ is the mean measurement vector for sample i, $\Sigma_{k}$ is the pooled covariance matrix, $\lambda_{k}$ is the variance–covariance matrix, and $x_k$ is the prior probability of class $k$ (52).

SPA and GA are variable selection techniques used to reduce the spectral data space into fewer variables. SPA works by minimizing $–\log (1 - g_{k})$, and GA works by simulating the data throughout an evolutionary process (54). The original space is maintained for both algorithms, and no transformation is made as in PCA. Therefore, the selected variables have the same meaning of the original ones (i.e., wavenumbers), and they are re-
sponsible for the region where there are more differences between the classes being analyzed or in other words, between the chemical changes.

For all classification models, samples were divided into training (70%), validation (15%), and prediction (15%) sets by applying Kennard–Stone uniform sampling selection algorithm (53). The training samples were used in the modeling procedure, whereas the prediction set was only used in the final classification evaluation using LDA and QDA discriminant approaches. The optimal number of variables for SPA and GA was determined with an average risk G of LDA/QDA misclassification. Such cost function is calculated in the validation set as

$$G = \frac{1}{N_v} \sum_{v=1}^{N_v} g_v$$

where $g_v$ is defined as

$$g_v = \frac{r^2(x_m, \mu_{m})}{\min_{(m)(n)}(r^2(x_m, \mu_{n}))}$$

The numerator is the squared Mahalanobis distance between the object $x_m$ and the sample mean $\mu_{(m)}$ of its true class, and the denominator is the squared Mahalanobis distance between the object $x_m$ and the mean of the closest wrong class (56).

The GA calculations were performed during 80 generations with 160 chromosomes each. One-point crossover and mutation probabilities were set to 60 and 10%, respectively. GA is a nondeterministic algorithm, which can give different results by using the same encoding and classification. Therefore, the algorithm was repeated three times starting from random initial populations, with the best solution resulting from the three realizations of GA used.

Sensitivity (probability that a test result will be positive when disease is present) and specificity (probability that a test result will be negative when disease is not present) were given by the following equations:

$$Sensitivity(\%) = \frac{TP}{TP + FN} \times 100, \hspace{1cm} [5]$$

$$Specificity(\%) = \frac{TN}{TN + FP} \times 100, \hspace{1cm} [6]$$

where TP is defined as true positive, FN is defined as false negative, TN is defined as true negative, and FP is defined as false positive.

Paraskevaidi et al.
Data Sharing. All data (raw spectra and preprocessed spectra) along with appropriate code identifiers will be uploaded onto the publicly accessible data repository Figrase.

Statistical Analysis. Differences between two groups were assessed using a Student’s t-test (two-tailed, nonparametric, Mann-Whitney test, 95% CI) in GraphPad Prism 6.0 (GraphPad Software). Statistical analysis was implemented at specific peaks pointed out after DBM spectra and cross-validated PCA-LDA as well as at scores plots as a whole. Before importing all of the information into GraphPad for additional statistical analysis, spectra were averaged every 10 (as 10 spectra were collected per individual) to account for differences between individuals rather than spectra. For the statistical analysis of three or more groups, one-way ANOVA was applied (nonparametric, Kruskal-Wallis test with a Dunn’s multiple comparison posttest). The data were expressed as the mean ± SD. A P value of 0.05 or less was considered significant in all statistical tests. Statistically significant differences were indicated with asterisks: *P < 0.05, **P < 0.01, ***P < 0.001, or ****P < 0.0001.

ACKNOWLEDGMENTS. We thank Mark Taylor, Kurimun Ismail, Yvonne Davidson, and Andrew Robinson for providing patient and sample information; Holly Butler for MATLAB tutorial; and Ketan Gajjar and Diane Halliwell for providing useful insights. M.P. was supported by the Rosemere Cancer Foundation. C.L.M.M. acknowledges Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Programa de Pesp (Processo em Quimioterapia), and Universidade Federal do Rio Grande do Norte (UFRN) for the research grant. K.M.G.L. was supported by Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) Grant 305962/2014-0.